SUPN Q4 2025 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SUPNSupernus Pharmaceuticals, Inc.

$3B

Q4 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$212M+21.5% YoY

Gross Profit

$189M89.1% margin

Operating Income

$14M6.5% margin

Net Income

-$4M-1.9% margin

EPS (Diluted)

$-0.07

QoQ Revenue Growth

+10.1%

Cash Flow

Operating Cash Flow

$47M

Free Cash Flow

$46M

Stock-Based Comp.

$33M

Balance Sheet

Total Assets

$1.5T

Total Liabilities

$390.9B

Stockholders' Equity

$1.1T

Cash & Equivalents

$128.4B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$212M	$174M	+21.5%
Gross Profit	$189M	$148M	+27.4%
Operating Income	$14M	$21M	-35.4%
Net Income	-$4M	$15M	-126.8%

Revenue Segments

Product

$158M44%

Qelbree

$81M22%

GOCOVRI

$39M11%

Collaboration Revenue

$33M9%

Royalty, License And Other Revenue

$21M6%

APOKYN

$10M3%

Trokendi Xr

$8M2%

Oxtellar X R

$7M2%

Manufactured Product, Other

$5M1%